APCT

Antiproton Beams for Cancer Therapy

Coordinatore	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.    more  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Carsten Cognome: Welsch Email: send email Telefono: +49 6221 516 335 Fax: -7526
Nazionalità Coordinatore	Germany [DE]
Totale costo	0 €
EC contributo	231˙422 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IIF-2008
Funding Scheme	MC-IIF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-06-15   -   2011-06-14

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.  Organization address address: Hofgartenstrasse 8 city: MUENCHEN postcode: 80539 contact info Titolo: Dr. Nome: Carsten Cognome: Welsch Email: send email Telefono: +49 6221 516 335 Fax: -7526	DE (MUENCHEN)	coordinator	231˙422.98

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Over the last 5 decades particle beam cancer therapy has shown its potential advantages in targeting tumors in critical areas. Multiple centers have been established around the world. To date about 60,000 patients have been treated with protons and 4000 patients have received heavy ion treatments. Despite the apparent success of these treatments a continued effort is necessary to provide the best possible therapeutic ratio – the ratio of the biological effective dose to the tumor compared to biological effect to normal tissue. Antiprotons have a significant advantage in this respect through the annihilation at the end of range. This annihilation event doubles the local energy deposition compared to protons and in addition delivers this dose in form of heavy ion recoils that exhibit an enhanced biological effect. A third advantage is the possibility of real-time imaging of the dose delivery process through detection of high-energy annihilation products. Especially in the case of radio-resistant tumors in close proximity of critical organs and structures, these advantages could provide the crucial difference between success and failure. We propose to firmly establish the biological advantages of antiprotons through a multitude of experiments using different cell lines and biological endpoints including clonogenic survival, genetic expressions, DNA modifications, to not only discern the potential tumor control but also to judge potential long term effects due to low dose delivery to normal tissue caused by secondary particles. Through this work we will generate the necessary input data to develop and benchmark a treatment planning system capable of generating comparative treatment plans for antiprotons and other external radiation therapy modalities. Using this treatment planning system we will identify a list of cases where the enhancement available through antiprotons can truly make a decisive difference.'

Introduzione (Teaser)

Despite extensive research, cancer remains a hot unresolved issue in terms of efficient treatment. Using antiproton particle beams, European researchers have developed a targeted approach of irradiation-induced therapy of small tumours.